Brought to you by 
Novartis, Hybridon team up for asthma, allergy drugs; ends
01 Dec 2009
Executive Summary
Hybridon (uses DNA chemistry to create therapeutics for cancer, asthma/allergies, and infectious diseases) has agreed to use its Immune Modulatory Oligonucleotide (IMO) platform to help Novartis discover and optimize toll-like receptor 9 (TLR9) compounds for asthma and allergies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis, Hybridon team up for asthma, allergy drugs; ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice